Lakshman Varanasi
Overview
Explore the profile of Lakshman Varanasi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozdian T, Holub D, Maceckova Z, Varanasi L, Rylova G, rehulka J, et al.
J Proteomics
. 2017 May;
162:73-85.
PMID: 28478306
Biological Significance: We have performed a whole-cell proteomic study of cellular response to oxaliplatin treatment, which is the drug predominantly used in the treatment of colorectal cancer. Compared to its...
2.
Schadich E, Hlavac J, Volna T, Varanasi L, Hajduch M, Dzubak P
Biomed Res Int
. 2016 Mar;
2016:2173275.
PMID: 26942188
Quercetin and phenylpropanoids are well known chemoprotective compounds identified in many plants. This study was aimed at determining their effects on activation of Nuclear factor erythroid 2-related factor 2 (Nrf2)...
3.
Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort
Koudelakova V, Trojanec R, Vrbkova J, Donevska S, Bouchalova K, Kolar Z, et al.
Genes Chromosomes Cancer
. 2016 Feb;
55(5):409-17.
PMID: 26847577
Eligibility to anti-HER2 therapy for breast tumors strictly depends on demonstrating HER2 overexpression (by immunohistochemistry) or HER2 gene amplification by in situ hybridization (ISH), usually defined by the ratio of...
4.
Rylova G, Ozdian T, Varanasi L, Soural M, Hlavac J, Holub D, et al.
Curr Drug Targets
. 2014 Nov;
16(1):60-76.
PMID: 25410410
Target discovery using the molecular approach, as opposed to the more traditional systems approach requires the study of the cellular or biological process underlying a condition or disease. The approaches...
5.
Do P, Varanasi L, Fan S, Li C, Kubacka I, Newman V, et al.
Genes Dev
. 2012 Apr;
26(8):830-45.
PMID: 22508727
Mutant p53 (mtp53) promotes chemotherapy resistance through multiple mechanisms, including disabling proapoptotic proteins and regulating gene expression. Comparison of genome wide analysis of mtp53 binding revealed that the ETS-binding site...
6.
Varanasi L, Do P, Goluszko E, Martinez L
Cell Cycle
. 2012 Mar;
11(6):1131-41.
PMID: 22391204
The E2F family of transcription factors responds to a variety of intracellular and extracellular signals and, as such, are key regulators of cell growth, differentiation and cell death. The cellular...
7.
Varanasi L, Hosler J
Biochim Biophys Acta
. 2011 Oct;
1817(4):545-51.
PMID: 22023935
We review studies of subunit III-depleted cytochrome c oxidase (CcO III (-)) that elucidate the structural basis of steady-state proton uptake from solvent into an internal proton transfer pathway. The...
8.
Varanasi L, Hosler J
Biochemistry
. 2011 Feb;
50(14):2820-8.
PMID: 21344856
To characterize protein structures that control proton uptake, we assayed forms of cytochrome c oxidase (CcO) containing a carboxyl or a thiol group in line with the initial, internal waters...
9.
Varanasi L, Mills D, Murphree A, Gray J, Purser C, Baker R, et al.
Biochemistry
. 2006 Dec;
45(50):14896-907.
PMID: 17154527
Subunit III of the three-subunit catalytic core of cytochrome c oxidase (CcO) contains no metal centers, but it does bind two lipids, within a deep cleft, in binding sites conserved...